Optogenetic Stimulation of Primary Cardiomyocytes Expressing ChR2

Area of Science:

• Cardiovascular Pharmacology
• Optogenetics
• Cellular Electrophysiology

Background:

• Non-clinical cardiovascular drug safety assessment is critical for new pharmaceutical development.
• Traditional cardiac safety testing often involves evaluating delayed rectifier potassium channel block and QT interval prolongation.
• Optogenetics offers a novel approach to modulate the electrophysiological properties of excitable cells.

Purpose of the Study:

• To develop and validate an optogenetic cell model for assessing cardiac drug safety.
• To investigate the use of channelrhodopsin-2 (ChR2) for light-induced modulation of cardiomyocyte function.
• To establish a cell-based assay for evaluating drug-induced changes in cardiac electrophysiology.

Main Methods:

• Primary neonatal cardiomyocytes were transduced with a lentiviral vector to express channelrhodopsin-2 (ChR2).
• Cells were subjected to optical stimulation using blue light.
• Transmembrane potential and intracellular calcium transients were measured following optical stimulation.

Main Results:

• Successful generation of cardiomyocytes expressing functional ChR2 (light-sensitive protein).
• Optical stimulation induced cardiomyocyte depolarization, evidenced by changes in membrane voltage.
• Light-induced stimulation also resulted in alterations in intracellular calcium levels.

Conclusions:

• The developed ChR2-expressing cardiomyocyte model provides a robust platform for optogenetic studies in cardiac research.
• This cell model is readily adaptable to standard laboratory cell culture systems.
• This approach presents a promising avenue for therapeutic research in cardiac optogenetics and drug safety evaluation.